JP2017514838A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017514838A5 JP2017514838A5 JP2016565398A JP2016565398A JP2017514838A5 JP 2017514838 A5 JP2017514838 A5 JP 2017514838A5 JP 2016565398 A JP2016565398 A JP 2016565398A JP 2016565398 A JP2016565398 A JP 2016565398A JP 2017514838 A5 JP2017514838 A5 JP 2017514838A5
- Authority
- JP
- Japan
- Prior art keywords
- pyrrolo
- amino
- methyl
- disease
- pyrimidin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 35
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 34
- 201000010099 disease Diseases 0.000 claims description 30
- 125000003831 tetrazolyl group Chemical group 0.000 claims description 28
- 206010028980 Neoplasm Diseases 0.000 claims description 11
- 201000011510 cancer Diseases 0.000 claims description 11
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims description 10
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims description 10
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims description 10
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims description 10
- 208000005176 Hepatitis C Diseases 0.000 claims description 8
- 208000006454 hepatitis Diseases 0.000 claims description 7
- 231100000283 hepatitis Toxicity 0.000 claims description 7
- 125000005842 heteroatom Chemical group 0.000 claims description 6
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 6
- -1 3-((2-amino-4- (pentylamino) -5H-pyrrolo [3,2-d] pyrimidin-5-yl) methyl) -4-methoxyphenyl Chemical group 0.000 claims description 5
- 208000023275 Autoimmune disease Diseases 0.000 claims description 5
- 206010004146 Basal cell carcinoma Diseases 0.000 claims description 5
- 206010006187 Breast cancer Diseases 0.000 claims description 5
- 208000026310 Breast neoplasm Diseases 0.000 claims description 5
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 5
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 5
- 206010009944 Colon cancer Diseases 0.000 claims description 5
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 5
- 208000011231 Crohn disease Diseases 0.000 claims description 5
- 201000004624 Dermatitis Diseases 0.000 claims description 5
- 201000004681 Psoriasis Diseases 0.000 claims description 5
- 206010039710 Scleroderma Diseases 0.000 claims description 5
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 5
- 208000024780 Urticaria Diseases 0.000 claims description 5
- 208000036142 Viral infection Diseases 0.000 claims description 5
- 208000009621 actinic keratosis Diseases 0.000 claims description 5
- 208000006673 asthma Diseases 0.000 claims description 5
- 206010006451 bronchitis Diseases 0.000 claims description 5
- 230000000694 effects Effects 0.000 claims description 5
- 208000002672 hepatitis B Diseases 0.000 claims description 5
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 5
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 5
- 208000015181 infectious disease Diseases 0.000 claims description 5
- 208000027866 inflammatory disease Diseases 0.000 claims description 5
- 206010025135 lupus erythematosus Diseases 0.000 claims description 5
- 201000006417 multiple sclerosis Diseases 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 208000023504 respiratory system disease Diseases 0.000 claims description 5
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 5
- 230000009385 viral infection Effects 0.000 claims description 5
- DAMMDMFUWSPYOK-FQEVSTJZSA-N (2S)-1-[[4-[[2-amino-4-(pentylamino)pyrrolo[3,2-d]pyrimidin-5-yl]methyl]-3-methoxyphenyl]methyl]pyrrolidine-2-carboxylic acid Chemical compound NC=1N=C(C2=C(N1)C=CN2CC2=C(C=C(CN1[C@@H](CCC1)C(=O)O)C=C2)OC)NCCCCC DAMMDMFUWSPYOK-FQEVSTJZSA-N 0.000 claims description 4
- 101000669402 Homo sapiens Toll-like receptor 7 Proteins 0.000 claims description 4
- WPXQRVLICLGUCL-UHFFFAOYSA-N N1N=NN=C1CC=1C=CC(=C(CN2C=CC=3N=C(N=C(C32)NCCCCC)N)C1)OC Chemical compound N1N=NN=C1CC=1C=CC(=C(CN2C=CC=3N=C(N=C(C32)NCCCCC)N)C1)OC WPXQRVLICLGUCL-UHFFFAOYSA-N 0.000 claims description 4
- JPMCLZUWKYUICG-UHFFFAOYSA-N N1N=NN=C1CCC=1C=CC(=C(CN2C=CC=3N=C(N=C(C32)NCCCCC)N)C1)OC Chemical compound N1N=NN=C1CCC=1C=CC(=C(CN2C=CC=3N=C(N=C(C32)NCCCCC)N)C1)OC JPMCLZUWKYUICG-UHFFFAOYSA-N 0.000 claims description 4
- YAPMMXHTJBSLQT-UHFFFAOYSA-N NC=1N=C(C2=C(N1)C=CN2CC=2C=C(C(=O)O)C=CC2OC)NCCCCC Chemical compound NC=1N=C(C2=C(N1)C=CN2CC=2C=C(C(=O)O)C=CC2OC)NCCCCC YAPMMXHTJBSLQT-UHFFFAOYSA-N 0.000 claims description 4
- DGBUFDBJFRAKLI-UHFFFAOYSA-N NC=1N=C(C2=C(N1)C=CN2CC=2C=C(C=CC2OC)CC(=O)O)NCCCCC Chemical compound NC=1N=C(C2=C(N1)C=CN2CC=2C=C(C=CC2OC)CC(=O)O)NCCCCC DGBUFDBJFRAKLI-UHFFFAOYSA-N 0.000 claims description 4
- 206010039085 Rhinitis allergic Diseases 0.000 claims description 4
- 102100039390 Toll-like receptor 7 Human genes 0.000 claims description 4
- 201000010105 allergic rhinitis Diseases 0.000 claims description 4
- 210000004027 cell Anatomy 0.000 claims description 4
- 208000035475 disorder Diseases 0.000 claims description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 4
- 230000002062 proliferating effect Effects 0.000 claims description 4
- 206010005003 Bladder cancer Diseases 0.000 claims description 3
- 208000035473 Communicable disease Diseases 0.000 claims description 3
- YATPCANSKUAXLN-HXUWFJFHSA-N NC=1N=C(C2=C(N1)C=CN2CC=2C=C(CN1[C@H](CCC1)C(=O)O)C=CC2OC)NCCCCC Chemical compound NC=1N=C(C2=C(N1)C=CN2CC=2C=C(CN1[C@H](CCC1)C(=O)O)C=CC2OC)NCCCCC YATPCANSKUAXLN-HXUWFJFHSA-N 0.000 claims description 3
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 3
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 3
- XBPWCXCQZZVVDJ-UHFFFAOYSA-N C(CCCCC)NC=1C2=C(N=C(N1)N)C=CN2CC2=C(C=CC(=C2)C2=NN=NN2)OC Chemical compound C(CCCCC)NC=1C2=C(N=C(N1)N)C=CN2CC2=C(C=CC(=C2)C2=NN=NN2)OC XBPWCXCQZZVVDJ-UHFFFAOYSA-N 0.000 claims description 2
- ZMXZKMDODWPMFT-UHFFFAOYSA-N COC1=C(CN2C=CC=3N=C(N=C(C32)NCCCCC)N)C=C(C=C1)C1=NN=NN1 Chemical compound COC1=C(CN2C=CC=3N=C(N=C(C32)NCCCCC)N)C=C(C=C1)C1=NN=NN1 ZMXZKMDODWPMFT-UHFFFAOYSA-N 0.000 claims description 2
- BIQPCKWQIOGLRO-UHFFFAOYSA-N COC1=C(CN2C=CC=3N=C(N=C(C32)NCCCCC)N)C=CC(=C1)C1=NN=NN1 Chemical compound COC1=C(CN2C=CC=3N=C(N=C(C32)NCCCCC)N)C=CC(=C1)C1=NN=NN1 BIQPCKWQIOGLRO-UHFFFAOYSA-N 0.000 claims description 2
- LERPKRPELMLJGL-UHFFFAOYSA-N FC(C=1C=CC(=C(CN2C=CC=3N=C(N=C(C32)NCCCCC)N)C1)OC)(C1=NN=NN1)F Chemical compound FC(C=1C=CC(=C(CN2C=CC=3N=C(N=C(C32)NCCCCC)N)C1)OC)(C1=NN=NN1)F LERPKRPELMLJGL-UHFFFAOYSA-N 0.000 claims description 2
- MHHIXFORUFMUNC-UHFFFAOYSA-N N1N=NN=C1C(C)(C)C=1C=CC(=C(CN2C=CC=3N=C(N=C(C32)NCCCCC)N)C1)OC Chemical class N1N=NN=C1C(C)(C)C=1C=CC(=C(CN2C=CC=3N=C(N=C(C32)NCCCCC)N)C1)OC MHHIXFORUFMUNC-UHFFFAOYSA-N 0.000 claims description 2
- ZJCMDZVSGDFLGB-KRWDZBQOSA-N N1N=NN=C1C(C)(C)C=1C=CC(=C(CN2C=CC=3N=C(N=C(C32)N[C@H](CO)CCCC)N)C1)OC Chemical compound N1N=NN=C1C(C)(C)C=1C=CC(=C(CN2C=CC=3N=C(N=C(C32)N[C@H](CO)CCCC)N)C1)OC ZJCMDZVSGDFLGB-KRWDZBQOSA-N 0.000 claims description 2
- LDGLRXLZQXFAQH-HNNXBMFYSA-N N1N=NN=C1CC=1C=CC(=C(CN2C=CC=3N=C(N=C(C32)N[C@H](CO)CCC)N)C1)OC Chemical compound N1N=NN=C1CC=1C=CC(=C(CN2C=CC=3N=C(N=C(C32)N[C@H](CO)CCC)N)C1)OC LDGLRXLZQXFAQH-HNNXBMFYSA-N 0.000 claims description 2
- QTGPSLBHJHDMAA-INIZCTEOSA-N N1N=NN=C1CC=1C=CC(=C(CN2C=CC=3N=C(N=C(C32)N[C@H](CO)CCCC)N)C1)OC Chemical compound N1N=NN=C1CC=1C=CC(=C(CN2C=CC=3N=C(N=C(C32)N[C@H](CO)CCCC)N)C1)OC QTGPSLBHJHDMAA-INIZCTEOSA-N 0.000 claims description 2
- VHPPHGRMEQLRTI-UHFFFAOYSA-N N1N=NN=C1COC=1C=CC(=C(CN2C=CC=3N=C(N=C(C32)NCCCCC)N)C1)OC Chemical compound N1N=NN=C1COC=1C=CC(=C(CN2C=CC=3N=C(N=C(C32)NCCCCC)N)C1)OC VHPPHGRMEQLRTI-UHFFFAOYSA-N 0.000 claims description 2
- YEGDWVRORNWXCA-UHFFFAOYSA-N NC=1N=C(C2=C(N1)C=CN2CC2=C(C=C(OCC(=O)O)C=C2)OC)NCCCCC Chemical compound NC=1N=C(C2=C(N1)C=CN2CC2=C(C=C(OCC(=O)O)C=C2)OC)NCCCCC YEGDWVRORNWXCA-UHFFFAOYSA-N 0.000 claims description 2
- LNDUPESSOYMSJP-HNNXBMFYSA-N NC=1N=C(C2=C(N1)C=CN2CC2=C(C=CC(=C2)C2=NN=NN2)OC)N[C@H](CO)CCCC Chemical compound NC=1N=C(C2=C(N1)C=CN2CC2=C(C=CC(=C2)C2=NN=NN2)OC)N[C@H](CO)CCCC LNDUPESSOYMSJP-HNNXBMFYSA-N 0.000 claims description 2
- XNZLVNCYIWAOFE-VQHVLOKHSA-N NC=1N=C(C2=C(N1)C=CN2CC=2C=C(C=CC2OC)/C=C/C(=O)O)NCCCCC Chemical compound NC=1N=C(C2=C(N1)C=CN2CC=2C=C(C=CC2OC)/C=C/C(=O)O)NCCCCC XNZLVNCYIWAOFE-VQHVLOKHSA-N 0.000 claims description 2
- YIHAVTSAPRGDNW-INIZCTEOSA-N NC=1N=C(C2=C(N1)C=CN2CC=2C=C(C=CC2OC)CC(=O)O)N[C@H](CO)CCCC Chemical compound NC=1N=C(C2=C(N1)C=CN2CC=2C=C(C=CC2OC)CC(=O)O)N[C@H](CO)CCCC YIHAVTSAPRGDNW-INIZCTEOSA-N 0.000 claims description 2
- YVHVMLRGFSLIND-UHFFFAOYSA-N NC=1N=C(C2=C(N1)C=CN2CC=2C=C(C=CC2OC)CCC(=O)O)NCCCCC Chemical compound NC=1N=C(C2=C(N1)C=CN2CC=2C=C(C=CC2OC)CCC(=O)O)NCCCCC YVHVMLRGFSLIND-UHFFFAOYSA-N 0.000 claims description 2
- NNOMZLJTXKTXQJ-KRWDZBQOSA-N NC=1N=C(C2=C(N1)C=CN2CC=2C=C(C=CC2OC)CCC(=O)O)N[C@H](CO)CCCC Chemical compound NC=1N=C(C2=C(N1)C=CN2CC=2C=C(C=CC2OC)CCC(=O)O)N[C@H](CO)CCCC NNOMZLJTXKTXQJ-KRWDZBQOSA-N 0.000 claims description 2
- AJLRGBCKWKXKJK-UHFFFAOYSA-N NC=1N=C(C2=C(N1)C=CN2CC=2C=C(C=CC2OC)P(O)(O)=O)NCCCCC Chemical compound NC=1N=C(C2=C(N1)C=CN2CC=2C=C(C=CC2OC)P(O)(O)=O)NCCCCC AJLRGBCKWKXKJK-UHFFFAOYSA-N 0.000 claims description 2
- MKYWYRKMBXGWJU-UHFFFAOYSA-N NC=1N=C(C2=C(N1)C=CN2CC=2C=C(CC=1N=NN(N1)CC(=O)O)C=CC2OC)NCCCCC Chemical compound NC=1N=C(C2=C(N1)C=CN2CC=2C=C(CC=1N=NN(N1)CC(=O)O)C=CC2OC)NCCCCC MKYWYRKMBXGWJU-UHFFFAOYSA-N 0.000 claims description 2
- FVQOAYDCQJAKTH-WOJBJXKFSA-N NC=1N=C(C2=C(N=1)C=CN2CC=1C=C(C=CC=1OC)CC[C@H](C[C@H](CC(=O)O)O)O)NCCCCC Chemical compound NC=1N=C(C2=C(N=1)C=CN2CC=1C=C(C=CC=1OC)CC[C@H](C[C@H](CC(=O)O)O)O)NCCCCC FVQOAYDCQJAKTH-WOJBJXKFSA-N 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 125000000217 alkyl group Chemical group 0.000 description 14
- 238000000034 method Methods 0.000 description 8
- 208000005440 Basal Cell Neoplasms Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 108010060825 Toll-Like Receptor 7 Proteins 0.000 description 1
- 102000008236 Toll-Like Receptor 7 Human genes 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461987321P | 2014-05-01 | 2014-05-01 | |
| US61/987,321 | 2014-05-01 | ||
| PCT/US2015/028264 WO2015168269A1 (en) | 2014-05-01 | 2015-04-29 | Compounds and compositions as toll-like receptor 7 agonists |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017514838A JP2017514838A (ja) | 2017-06-08 |
| JP2017514838A5 true JP2017514838A5 (enExample) | 2018-04-05 |
| JP6484253B2 JP6484253B2 (ja) | 2019-03-13 |
Family
ID=53284501
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016565398A Active JP6484253B2 (ja) | 2014-05-01 | 2015-04-29 | Ｔｏｌｌ様受容体７アゴニストとしての化合物および組成物 |
Country Status (30)
| Country | Link |
|---|---|
| US (1) | US9902730B2 (enExample) |
| EP (1) | EP3137470B1 (enExample) |
| JP (1) | JP6484253B2 (enExample) |
| KR (1) | KR102139847B1 (enExample) |
| CN (1) | CN106232603B (enExample) |
| AP (1) | AP2016009485A0 (enExample) |
| AR (1) | AR100244A1 (enExample) |
| AU (1) | AU2015253215B2 (enExample) |
| BR (1) | BR112016025423A2 (enExample) |
| CA (1) | CA2946408C (enExample) |
| CL (1) | CL2016002751A1 (enExample) |
| CR (1) | CR20160512A (enExample) |
| CU (1) | CU24401B1 (enExample) |
| DO (1) | DOP2016000295A (enExample) |
| EA (1) | EA030603B1 (enExample) |
| ES (1) | ES2877050T3 (enExample) |
| GT (1) | GT201600233A (enExample) |
| IL (1) | IL248347B (enExample) |
| MX (1) | MX362341B (enExample) |
| NI (1) | NI201600164A (enExample) |
| NZ (1) | NZ724792A (enExample) |
| PE (1) | PE20170325A1 (enExample) |
| PH (1) | PH12016501966B1 (enExample) |
| PL (1) | PL3137470T3 (enExample) |
| PT (1) | PT3137470T (enExample) |
| SG (1) | SG11201608161VA (enExample) |
| SV (1) | SV2016005311A (enExample) |
| TW (1) | TWI666212B (enExample) |
| UY (1) | UY36103A (enExample) |
| WO (1) | WO2015168269A1 (enExample) |
Families Citing this family (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2908150T3 (es) | 2014-05-01 | 2022-04-27 | Novartis Ag | Compuestos y composiciones como agonistas del receptor de tipo Toll 7 |
| HUE054672T2 (hu) | 2014-08-15 | 2021-09-28 | Chia Tai Tianqing Pharmaceutical Group Co Ltd | TLR7 agonistaként alkalmazott pirrolopirimidin vegyületek |
| MY188211A (en) | 2015-03-04 | 2021-11-24 | Gilead Sciences Inc | Toll-like receptor modulating 4,6-diamino-pyrido[3,2-d]pyrimidine compounds |
| WO2017015267A1 (en) * | 2015-07-20 | 2017-01-26 | Genzyme Corporation | Colony stimulating factor-1 receptor (csf-1r) inhibitors |
| MA44334A (fr) | 2015-10-29 | 2018-09-05 | Novartis Ag | Conjugués d'anticorps comprenant un agoniste du récepteur de type toll |
| CN107043378A (zh) * | 2016-02-05 | 2017-08-15 | 正大天晴药业集团股份有限公司 | 一种吡咯并[3,2-d]嘧啶类化合物的制备方法及其中间体 |
| CN107043380A (zh) * | 2016-02-05 | 2017-08-15 | 正大天晴药业集团股份有限公司 | 一种tlr7激动剂的马来酸盐、其晶型c、晶型d、晶型e、制备方法和用途 |
| CN107043379A (zh) * | 2016-02-05 | 2017-08-15 | 正大天晴药业集团股份有限公司 | 一种tlr7激动剂的晶型a、其制备方法和医药用途 |
| CN107043377A (zh) * | 2016-02-05 | 2017-08-15 | 正大天晴药业集团股份有限公司 | 一种tlr7激动剂的三氟乙酸盐、晶型b及其制备方法、药物组合物和用途 |
| US10640499B2 (en) | 2016-09-02 | 2020-05-05 | Gilead Sciences, Inc. | Toll like receptor modulator compounds |
| MA46093A (fr) | 2016-09-02 | 2021-05-19 | Gilead Sciences Inc | Composés modulateurs du recepteur de type toll |
| FI3526323T3 (fi) | 2016-10-14 | 2023-06-06 | Prec Biosciences Inc | Hepatiitti B -viruksen genomissa oleville tunnistussekvensseille spesifisiä muokattuja meganukleaaseja |
| CN106727768A (zh) * | 2017-02-06 | 2017-05-31 | 灞卞嘲 | 一种治疗子宫内膜炎的药物组合物 |
| US10457681B2 (en) | 2017-08-16 | 2019-10-29 | Bristol_Myers Squibb Company | Toll-like receptor 7 (TLR7) agonists having a tricyclic moiety, conjugates thereof, and methods and uses therefor |
| US10508115B2 (en) | 2017-08-16 | 2019-12-17 | Bristol-Myers Squibb Company | Toll-like receptor 7 (TLR7) agonists having heteroatom-linked aromatic moieties, conjugates thereof, and methods and uses therefor |
| US10494370B2 (en) | 2017-08-16 | 2019-12-03 | Bristol-Myers Squibb Company | Toll-like receptor 7 (TLR7) agonists having a pyridine or pyrazine moiety, conjugates thereof, and methods and uses therefor |
| US10472361B2 (en) | 2017-08-16 | 2019-11-12 | Bristol-Myers Squibb Company | Toll-like receptor 7 (TLR7) agonists having a benzotriazole moiety, conjugates thereof, and methods and uses therefor |
| US10487084B2 (en) | 2017-08-16 | 2019-11-26 | Bristol-Myers Squibb Company | Toll-like receptor 7 (TLR7) agonists having a heterobiaryl moiety, conjugates thereof, and methods and uses therefor |
| WO2019066571A2 (ko) | 2017-09-28 | 2019-04-04 | 연세대학교 산학협력단 | 골수유래 면역반응 억제세포의 제조방법, 이에 의해 제조된 골수유래 면역반응 억제세포 및 그 용도 |
| KR102492115B1 (ko) | 2017-12-20 | 2023-01-27 | 인스티튜트 오브 오가닉 케미스트리 앤드 바이오케미스트리 에이에스 씨알 브이.브이.아이. | Sting 어댑터 단백질을 활성화하는 포스포네이트 결합을 가진 2'3' 사이클릭 다이뉴클레오티드 |
| CA3084569A1 (en) | 2017-12-20 | 2019-06-27 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
| US10836769B2 (en) | 2018-02-26 | 2020-11-17 | Gilead Sciences, Inc. | Substituted pyrrolizine compounds and uses thereof |
| US10870691B2 (en) | 2018-04-05 | 2020-12-22 | Gilead Sciences, Inc. | Antibodies and fragments thereof that bind hepatitis B virus protein X |
| TWI833744B (zh) | 2018-04-06 | 2024-03-01 | 捷克科學院有機化學與生物化學研究所 | 3'3'-環二核苷酸 |
| TW202005654A (zh) | 2018-04-06 | 2020-02-01 | 捷克科學院有機化學與生物化學研究所 | ２，２，─環二核苷酸 |
| TWI818007B (zh) | 2018-04-06 | 2023-10-11 | 捷克科學院有機化學與生物化學研究所 | 2'3'-環二核苷酸 |
| US11142750B2 (en) | 2018-04-12 | 2021-10-12 | Precision Biosciences, Inc. | Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome |
| WO2019209811A1 (en) | 2018-04-24 | 2019-10-31 | Bristol-Myers Squibb Company | Macrocyclic toll-like receptor 7 (tlr7) agonists |
| TW202014193A (zh) | 2018-05-03 | 2020-04-16 | 捷克科學院有機化學與生物化學研究所 | 包含碳環核苷酸之2’3’－環二核苷酸 |
| US12128047B2 (en) * | 2018-05-25 | 2024-10-29 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | TLR7 agonist and pharmaceutical combination thereof for treating lung cancer |
| WO2020028097A1 (en) | 2018-08-01 | 2020-02-06 | Gilead Sciences, Inc. | Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid |
| US11554120B2 (en) | 2018-08-03 | 2023-01-17 | Bristol-Myers Squibb Company | 1H-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (TLR7) agonists and methods and uses therefor |
| WO2020092528A1 (en) | 2018-10-31 | 2020-05-07 | Gilead Sciences, Inc. | Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity |
| HRP20240541T1 (hr) | 2018-10-31 | 2024-07-05 | Gilead Sciences, Inc. | Supstituirani spojevi 6-azabenzimidazola kao inhibitori hpk1 |
| WO2020112937A1 (en) * | 2018-11-30 | 2020-06-04 | Nimbus Lakshmi, Inc. | Tyk2 inhibitors and uses thereof |
| WO2020178768A1 (en) | 2019-03-07 | 2020-09-10 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator |
| EP3935066A1 (en) | 2019-03-07 | 2022-01-12 | Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. | 3'3'-cyclic dinucleotides and prodrugs thereof |
| US12318403B2 (en) | 2019-03-07 | 2025-06-03 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2′3′-cyclic dinucleotides and prodrugs thereof |
| JP7598875B2 (ja) | 2019-04-12 | 2024-12-12 | リボサイエンス リミティド ライアビリティ カンパニー | エクトヌクレオチドピロホスファターゼホスホジエステラーゼ１阻害剤としての二環式ヘテロアリール誘導体 |
| TW202210480A (zh) | 2019-04-17 | 2022-03-16 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| TWI751517B (zh) | 2019-04-17 | 2022-01-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| EP3972695A1 (en) | 2019-05-23 | 2022-03-30 | Gilead Sciences, Inc. | Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors |
| JP7706210B2 (ja) * | 2019-06-10 | 2025-07-11 | ストロ バイオファーマ インコーポレーテッド | ５Ｈ－ピロロ［３，２－ｄ］ピリミジン－２，４－ジアミノ化合物およびその抗体コンジュゲート |
| TWI879779B (zh) | 2019-06-28 | 2025-04-11 | 美商基利科學股份有限公司 | 類鐸受體調節劑化合物的製備方法 |
| WO2021034804A1 (en) | 2019-08-19 | 2021-02-25 | Gilead Sciences, Inc. | Pharmaceutical formulations of tenofovir alafenamide |
| JP7398556B2 (ja) | 2019-09-30 | 2023-12-14 | ギリアード サイエンシーズ， インコーポレイテッド | Ｈｂｖワクチン及びｈｂｖを治療する方法 |
| WO2021113765A1 (en) | 2019-12-06 | 2021-06-10 | Precision Biosciences, Inc. | Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome |
| EP4097103A1 (en) | 2020-01-27 | 2022-12-07 | Bristol-Myers Squibb Company | 1h-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (tlr7) agonists |
| EP4097108A1 (en) | 2020-01-27 | 2022-12-07 | Bristol-Myers Squibb Company | 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS |
| WO2021154663A1 (en) | 2020-01-27 | 2021-08-05 | Bristol-Myers Squibb Company | 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS |
| EP4097107A1 (en) | 2020-01-27 | 2022-12-07 | Bristol-Myers Squibb Company | C3-substituted 1h-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (tlr7) agonists |
| WO2021154664A1 (en) | 2020-01-27 | 2021-08-05 | Bristol-Myers Squibb Company | 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS |
| US20230041738A1 (en) | 2020-01-27 | 2023-02-09 | Bristol-Myers Squibb Company | 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS |
| KR20220132594A (ko) | 2020-01-27 | 2022-09-30 | 브리스톨-마이어스 스큅 컴퍼니 | 톨-유사 수용체 7 (TLR7) 효능제로서의 1H-피라졸로[4,3-d]피리미딘 화합물 |
| KR20220132593A (ko) | 2020-01-27 | 2022-09-30 | 브리스톨-마이어스 스큅 컴퍼니 | 톨-유사 수용체 7 (TLR7) 효능제로서의 1H-피라졸로[4,3-d]피리미딘 화합물 |
| EP4097102A1 (en) * | 2020-01-27 | 2022-12-07 | Bristol-Myers Squibb Company | 1h-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (tlr7) agonists |
| WO2021188959A1 (en) | 2020-03-20 | 2021-09-23 | Gilead Sciences, Inc. | Prodrugs of 4'-c-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same |
| JP2024500919A (ja) | 2020-12-23 | 2024-01-10 | ジェンザイム・コーポレーション | 重水素化コロニー刺激因子－１受容体（ｃｓｆ－１ｒ）阻害剤 |
| WO2022241134A1 (en) | 2021-05-13 | 2022-11-17 | Gilead Sciences, Inc. | COMBINATION OF A TLR8 MODULATING COMPOUND AND ANTI-HBV siRNA THERAPEUTICS |
| AU2022297367B2 (en) | 2021-06-23 | 2025-04-10 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| CA3222277A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| CN117377671A (zh) | 2021-06-23 | 2024-01-09 | 吉利德科学公司 | 二酰基甘油激酶调节化合物 |
| IL309378A (en) | 2021-06-23 | 2024-02-01 | Gilead Sciences Inc | Diacylglyercol kinase modulating compounds |
| US20250345389A1 (en) | 2024-05-13 | 2025-11-13 | Gilead Sciences, Inc. | Combination therapies |
| WO2025240244A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies comprising bulevirtide and lonafarnib for use in the treatment of hepatitis d virus infection |
| WO2025240242A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with ribavirin |
| WO2025240246A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with ribavirin |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0530537B1 (en) * | 1991-08-12 | 1997-01-08 | Takeda Chemical Industries, Ltd. | Condensed pyrimidine derivatives, their production and use as antitumor agents |
| US5834469A (en) | 1994-06-09 | 1998-11-10 | Smithkline Beecham Corporation | Endothelin receptor antagonists |
| WO2000068213A1 (en) | 1999-05-05 | 2000-11-16 | Aventis Pharma Limited | Substituted bicyclic compounds |
| DK1713806T3 (da) | 2004-02-14 | 2013-08-05 | Irm Llc | Forbindelser og sammensætninger som proteinkinaseinhibitorer |
| JPWO2005092892A1 (ja) * | 2004-03-26 | 2008-02-14 | 大日本住友製薬株式会社 | ８−オキソアデニン化合物 |
| WO2005107760A1 (en) * | 2004-04-30 | 2005-11-17 | Irm Llc | Compounds and compositions as inducers of keratinocyte differentiation |
| ZA200610669B (en) * | 2004-06-02 | 2008-06-25 | Takeda Pharmaceutical | Fused heterocyclic compound |
| US7507740B2 (en) | 2004-06-02 | 2009-03-24 | Takeda Pharmaceutical Company Limited | Fused heterocyclic compound |
| MX2007011316A (es) * | 2005-03-15 | 2007-11-12 | Irm Llc | Compuestos y composiciones como inhibidores de cinasa de proteina. |
| US20090105212A1 (en) * | 2005-09-22 | 2009-04-23 | Dainippon Sumitomo Pharma Co., Ltd. a corporation of Japan | Novel adenine compound |
| CA2691444C (en) * | 2007-06-29 | 2016-06-14 | Gilead Sciences, Inc. | Purine derivatives and their use as modulators of toll-like receptor 7 |
| UY31631A1 (es) | 2008-02-06 | 2009-09-30 | Nuevos derivados de 7-fenil-7h-pirrolo-[2,3d]-pirimidin-2-il-amino, sales de los mismos, procesos para su preparacion, composiciones farmacéuticas que los comprenden y aplicaciones | |
| WO2010048149A2 (en) | 2008-10-20 | 2010-04-29 | Kalypsys, Inc. | Heterocyclic modulators of gpr119 for treatment of disease |
| AR074760A1 (es) | 2008-12-18 | 2011-02-09 | Metabolex Inc | Agonistas del receptor gpr120 y usos de los mismos en medicamentos para el tratamiento de diabetes y el sindrome metabolico. |
| US20130137709A1 (en) | 2010-05-05 | 2013-05-30 | Nathanael S. Gray | Compounds that modulate EGFR activity and methods for treating or preventing conditions therewith |
| RU2585177C2 (ru) * | 2010-06-23 | 2016-05-27 | Ханми Сайенс Ко., Лтд. | Новые конденсированные пиримидиновые производные для ингибирования тирозинкиназной активности |
| WO2012066336A1 (en) * | 2010-11-19 | 2012-05-24 | Astrazeneca Ab | Benzylamine compounds as toll -like receptor 7 agonists |
| EP2570125A1 (en) | 2011-09-16 | 2013-03-20 | Almirall, S.A. | Ep1 receptor ligands |
| US8697888B2 (en) | 2012-01-06 | 2014-04-15 | Vanderbilt University | Substituted (1-(methylsulfonyl)azetidin-3-yl)(heterocycloalkyl)methanone analogs as antagonists of muscarinic acetylcholine M1 receptors |
| MX365114B (es) * | 2012-10-10 | 2019-05-23 | Janssen Sciences Ireland Uc | Derivados pirrolo[3,2-d]pirimidinicos para el tratamiento de infecciones viricas y otras enfermedades. |
| ES2908150T3 (es) | 2014-05-01 | 2022-04-27 | Novartis Ag | Compuestos y composiciones como agonistas del receptor de tipo Toll 7 |
| AR103467A1 (es) | 2015-01-23 | 2017-05-10 | Kyoyu Agri Co Ltd | Derivado de pirazolilpirazol sustituido y su empleo como herbicida |
-
2015
- 2015-04-29 AP AP2016009485A patent/AP2016009485A0/en unknown
- 2015-04-29 EP EP15727098.4A patent/EP3137470B1/en active Active
- 2015-04-29 EA EA201692177A patent/EA030603B1/ru not_active IP Right Cessation
- 2015-04-29 PL PL15727098T patent/PL3137470T3/pl unknown
- 2015-04-29 PE PE2016002146A patent/PE20170325A1/es unknown
- 2015-04-29 CN CN201580021618.9A patent/CN106232603B/zh active Active
- 2015-04-29 PT PT157270984T patent/PT3137470T/pt unknown
- 2015-04-29 MX MX2016014305A patent/MX362341B/es active IP Right Grant
- 2015-04-29 JP JP2016565398A patent/JP6484253B2/ja active Active
- 2015-04-29 AU AU2015253215A patent/AU2015253215B2/en not_active Ceased
- 2015-04-29 NZ NZ724792A patent/NZ724792A/en not_active IP Right Cessation
- 2015-04-29 KR KR1020167030101A patent/KR102139847B1/ko not_active Expired - Fee Related
- 2015-04-29 UY UY0001036103A patent/UY36103A/es not_active Application Discontinuation
- 2015-04-29 SG SG11201608161VA patent/SG11201608161VA/en unknown
- 2015-04-29 CA CA2946408A patent/CA2946408C/en not_active Expired - Fee Related
- 2015-04-29 US US15/307,525 patent/US9902730B2/en active Active
- 2015-04-29 ES ES15727098T patent/ES2877050T3/es active Active
- 2015-04-29 CR CR20160512A patent/CR20160512A/es unknown
- 2015-04-29 BR BR112016025423A patent/BR112016025423A2/pt not_active IP Right Cessation
- 2015-04-29 CU CU2016000160A patent/CU24401B1/es unknown
- 2015-04-29 WO PCT/US2015/028264 patent/WO2015168269A1/en not_active Ceased
- 2015-04-30 AR ARP150101310A patent/AR100244A1/es unknown
- 2015-04-30 TW TW104113993A patent/TWI666212B/zh not_active IP Right Cessation
-
2016
- 2016-10-04 PH PH12016501966A patent/PH12016501966B1/en unknown
- 2016-10-13 IL IL248347A patent/IL248347B/en active IP Right Grant
- 2016-10-28 CL CL2016002751A patent/CL2016002751A1/es unknown
- 2016-10-28 NI NI201600164A patent/NI201600164A/es unknown
- 2016-10-31 GT GT201600233A patent/GT201600233A/es unknown
- 2016-11-01 DO DO2016000295A patent/DOP2016000295A/es unknown
- 2016-11-01 SV SV2016005311A patent/SV2016005311A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017514838A5 (enExample) | ||
| JP2017514839A5 (enExample) | ||
| JP2019501133A5 (enExample) | ||
| JP2019510796A5 (enExample) | ||
| JP2011207901A5 (enExample) | ||
| ME02150B (me) | Derivati piperidinona kao inhibitori mdm2 za lečenje kancera | |
| JP2012525393A5 (enExample) | ||
| JP2014511891A5 (enExample) | ||
| JP2017516771A5 (enExample) | ||
| JP2014505735A5 (enExample) | ||
| JP2014502641A5 (enExample) | ||
| JP2015511638A5 (enExample) | ||
| JP2015529235A5 (enExample) | ||
| JP2015508103A5 (enExample) | ||
| JP2011246469A5 (enExample) | ||
| JP2013502431A5 (enExample) | ||
| RU2017105353A (ru) | Соединения | |
| JP2015508749A5 (enExample) | ||
| HRP20171808T1 (hr) | Spojevi policikličkog karbamoilpiridona i njihova uporaba za liječenje hiv infekcija | |
| JP2016510326A5 (enExample) | ||
| JP2013534248A5 (enExample) | ||
| JP2013506639A5 (enExample) | ||
| JP2014502972A5 (enExample) | ||
| JP2017520613A5 (enExample) | ||
| JP2019511542A5 (enExample) |